Well, that was much ado about nothing:
“There is a reasonable suspicion we better learn more and watch this affair more closely before we launch into massive use of this drug,” said Jules Hirsch, a panel member and professor at Rockefeller University in New York, according to Dow Jones.While the FDA is not required to follow its committees’ advice, it usually does so. And most observers think the agency, which has previously refused to approve Acomplia because of its side effects, is likely to side with the committee on this one. Sanofi’s stock, which has been falling for more than a week, was down nearly 3% today.
Derek Lowe called it right.
